AVXL Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
-6737000
-203.9%
6.5M
-4.4%
6.8M
-37.5%
10.8M
-25.0%
14.5M
R&D
-4705000
-212.2%
4.2M
-10.0%
4.7M
-36.2%
7.3M
-26.8%
10.0M
SG&A
-2032000
-188.7%
2.3M
+7.8%
2.1M
-40.1%
3.5M
-21.1%
4.5M
Operating Income
6.7M
+203.9%
-6484000
+4.4%
-6782000
+37.5%
-10844000
+25.0%
-14459000
EBITDA
6.7M
+203.9%
-6484000
+4.4%
-6782000
+37.5%
-10844000
+25.0%
-14459000
Net Income
7.8M
+246.6%
-5338000
+6.0%
-5681000
+42.2%
-9827000
+25.8%
-13243000
EPS (Basic)
$0.08
+233.3%
$-0.06
+0.0%
$-0.06
+45.5%
$-0.11
+31.3%
$-0.16
EPS (Diluted)
$0.08
+233.3%
$-0.06
+0.0%
$-0.06
+45.5%
$-0.11
+31.3%
$-0.16
Shares (Diluted)
92.9M
+0.2%
92.7M
+4.1%
89.0M
+3.6%
85.9M
+0.6%
85.4M
Anavex Life Sciences (AVXL) โ€” Financials